Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trialIf you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease -- Hoops et al. 73 (21): 1738 -- Neurology
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease S. Hoops, BA, S. Nazem, BA, A. D. Siderowf, MD, J. E. Duda, MD, S. X. Xie, PhD, M. B. Stern, MD and D. Weintraub, MD From the Departments of Psychiatry (S.H., S.N., D.W.), Neurology (A.D.S., J.E.D., M.B.S., D.W.), and Biostatistics and Epidemiology (S.X.X.), University of Pennsylvania; and Parkinsons Disease R
A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease
A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease J Grace1, M M Amick1, J H Friedman2 1 Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, USA 2 Clinical Neurosciences, Alpert Medical School of Brown University, Providence, RI, USA Dr J Grace, Medical Rehabilitation, Memorial Hospital of Rhode Island, 111 Brewster Stree
1
リリース、障害情報などのサービスのお知らせ
最新の人気エントリーの配信
j次のブックマーク
k前のブックマーク
lあとで読む
eコメント一覧を開く
oページを開く
